Home|Journals|Articles by Year|Audio Abstracts
 

Review Article



Recent advances in peptide-based nanovaccines for re-emerging and emerging infectious diseases

Fredmoore Orosco.




Abstract

Peptide-based nanovaccines have emerged as promising strategies for combating re-emerging and emerging infectious diseases. They exhibit excellent immunogenicity and therapeutic potential. They have shown the ability to elicit robust immune responses, including activation of antigen-presenting cells, induction of specific antibodies and T-cell responses, and generation of memory immune cells. This comprehensive review article aims to provide a thorough overview of recent advances in the field, including self-assembling peptide-based nanovaccines, immunological mechanisms, structural design approaches, and utilization of various nanomaterials. Overall, peptide-based nanovaccines hold great promise in combating infectious diseases. Precise design and assembly of targeted and tailored immune responses will enable effective prevention, treatment, and long-term protection. Further research is needed to optimize their efficacy, safety, and clinical translation. The knowledge gained from these studies will pave the way for a future with more effective immunotherapeutic interventions against infectious diseases.

Key words: immune response, infectious diseases, nanotechnology, peptide-based nanovaccines






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.